Multi-kinase-IN-4

• UNSPSC Description:

  Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer[1].

• Target Antigen:

  Apoptosis; CDK; EGFR; Necroptosis; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/multi-kinase-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(C/C=C(CC)\C)C(SCC2=CC=C(Cl)C=C2)=NC3=C1C=C(F)C=C3

• Molecular Weight:

  402.91

• References & Citations:

  [1]Ali Altharawi, et al. Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023 Jul; 28(14): 5548.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported